Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: Diagnosis is dependent on the intensity of investigation

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 2, 2008, Pages 271-278

  Connolly, David ^a   Black, Amanda ^b   Gavin, Anna ^b   Keane, Patrick F ^a   Murray, Liam J ^b  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

AGED; CAUSE OF DEATH; COHORT STUDIES; EARLY DIAGNOSIS; HUMANS; MALE; MIDDLE AGED; NORTHERN IRELAND; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 39449139858     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0515     Document Type: Article

References (30)

1. American Cancer Society. Cancer facts and figures, 2006. Atlanta: American Cancer Society; 2006. Available from: http://www.cancer.org/downloads/ STT/CAFF2006PWSecured.pdf.
2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-8.
3. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95:1276-99.
4. Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Huntingt) 2000;14:267, 72, 277-8, 280 passim.
5. UK National Screening Committee. Second Report of the UK National Screening Committee. London: Department of Health; 2000.
6. Catalona WJ, Hudson MA, Scardino PT, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994;152:2037-42.
7. Antenor JA, Han M, Roehl KA, Nadler RB, Catalona WJ. Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J Urol 2004;172:90-3.
8. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
9. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA 2005;294:66-70.
10. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98:529-34.
11. Northern Ireland Statistics and Research Agency. Northern Ireland Census 2001 Key Statistics. Belfast: National Statistics; 2002. Available from: http://www.nisranew.nisra.gov.uk/census/Census2001Output/KeyStatistics/keystats. html.
12. Gavin A, McCarron P, Middleton RJ, et al. Evidence of prostate cancer screening in a UK region. BJU Int 2004;93:730-4.
13. Connolly D. Long term follow-up of men with elevated prostate specific antigen levels: a population based study. MD thesis. Belfast: Queen's University Belfast; 2007.
14. WHO. International statistical classification of diseases and related health problems. Tenth revision. Vol. 1. Geneva: WHO; 1992.
15. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78.
16. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101.
17. Aus G, Damber JE, Khatami A, Lilja H, Stranne J, Hugosson J. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med 2005;165:1857-61.
18. Gavin A, Hughes J, Ranaghan L, Fitzpatrick D. Cancer Services Audit 1996 & 2001, Prostate. Northern Ireland Cancer Registry; 2005.
19. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-94.
20. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001;58:411-6.
21. Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006;67:316-20.
22. McGregor M, Hanley JA, Boivin JF, McLean RG. Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 1998;159:1368-72.
23. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-90.
24. 1c) prostate cancer. JAMA 1994;271:368-74.
25. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994;152:1714-20.
26. Loeb S, Gonzalez CM, Roehl KA, et al. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol 2006;175:902-6.
27. 1C adenocarcinoma of the prostate. J Urol 1997;157:2206-9.
28. Ries LAG, Eisner MP, Kosary CL, et al., editors. SEER Cancer Statistics Review, 1975-2003. Bethesda (MD): National Cancer Institute; 2006. Available from: http://seer.cancer.gov/csr/1975_2003/results_merged/topic_annualrates.pdf.
29. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98:1521-7.
30. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. Volume VIII. Lyon (France): IARC Scientific Publications No. 155; 2002.